Ten Things to Know About Consolidation in Health Care Provider Markets

Mergers and acquisitions involving hospitals and other health care providers are drawing attention from federal and state regulators, including the Federal Trade Commission, and policymakers amid concerns that such consolidations can reduce competition and contribute to the high costs of health care.

A new KFF brief examines and summarizes the evidence about consolidation among health care providers as more community hospitals become part of a larger system, and more physicians are in practices owned by hospitals and systems.

Drawing from a wide variety of sources, the brief offers insights into the pace of consolidation among providers, its impact on prices and quality, and policy proposals aimed at reducing consolidation and increasing competition, such as:

  • Following a wave of consolidation in the early- and mid-1990s, there were 1,573 hospital mergers from 1998 to 2017 and another 428 hospital and health system mergers announced from 2018 to 2023.
  • The share of physicians working for a hospital or in a practice owned at least partially by a hospital or health system increased from 29% in 2012 to 41% in 2022. In addition, a growing share of physician practices are owned by other corporate entities, including insurance companies.
  • While consolidation may allow providers to operate more efficiently, a substantial body of research shows that it generally leads to higher health care prices. The evidence overall does not show clear gains in access or quality.
  • Some studies have found that hospital consolidation can lead to lower wages for some skilled workers, such as nurses. The broader evidence on employment and compensation effects is limited, including the extent to which mergers that prevent closures could preserve jobs.
  • State and federal policy proposals to address consolidation and increase competition include strengthening antitrust enforcement, reducing financial incentives for provider consolidation, increasing price transparency, and allowing more providers to enter the market. Each of these proposals would involve tradeoffs, and the extent to which they can reduce health costs is unclear since many markets already are highly concentrated.

The brief is part of KFF’s expanding work examining the business practices of hospitals and other providers, and their impact on costs and affordability.

 

Source Link

Recommended Articles

CMS Finalizes Major Changes To ACA Exchanges, Including Greater Access To Catastrophic Plans

Editor’s Note: Covered California is a State-Based Marketplace (SBM). For details on how these new rules will impact Covered California and other SBMs we recommend the following Princeton University linked report: (Broker rule changes appear at the bottom of the Princeton analysis.) https://shvs.org/wp-content/uploads/2025/06/SHVS_2025-Final-Marketplace-Integrity-Rule.pdf.   The Trump administration on Friday finalized a major rule reshaping the ...

Read More

Eroding ACA Enrollment Portends Higher Insurance Rates

Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s record enrollment. For ...

Read More

White House Adds Generic Drugs To Direct-To-Consumer TrumpRx Site

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx, in a bid to expand a platform that is key to his administration’s efforts to lower prescription drug costs in the U.S. The administration is adding more than 600 generic drugs to the site, President Donald Trump said at an event ...

Read More

Supreme Court Rejects Big Pharma Appeals Challenging Negotiated Drug Prices In Medicare

The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs. The court’s decision to deny ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square